Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

8,620 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical pharmacological study of a plasma-derived factor VIIa and factor X mixture (MC710) in haemophilia patients with inhibitors--phase I trial.
Shirahata A, Fukutake K, Mimaya J, Takamatsu J, Shima M, Hanabusa H, Takedani H, Takashima Y, Matsushita T, Tawa A, Higasa S, Takata N, Sakai M, Kawakami K, Ohashi Y, Saito H. Shirahata A, et al. Among authors: saito h. Haemophilia. 2012 Jan;18(1):94-101. doi: 10.1111/j.1365-2516.2011.02548.x. Epub 2011 Apr 28. Haemophilia. 2012. PMID: 21535327 Clinical Trial.
Clinical trial to investigate the pharmacokinetics, pharmacodynamics, safety, and efficacy of recombinant factor VIIa in Japanese patients with hemophilia with inhibitors.
Shirahata A, Kamiya T, Takamatsu J, Kojima T, Fukutake K, Arai M, Hanabusa H, Tagami H, Yoshioka A, Shima GM, Naka GH, Fujita GS, Minamoto Y, Kamizono J, Saito H. Shirahata A, et al. Among authors: saito h. Int J Hematol. 2001 Jun;73(4):517-25. doi: 10.1007/BF02994016. Int J Hematol. 2001. PMID: 11503968 Clinical Trial.
Results of clot waveform analysis and thrombin generation test for a plasma-derived factor VIIa and X mixture (MC710) in haemophilia patients with inhibitors--phase I trial: 2nd report.
Shirahata A, Fukutake K, Mimaya J, Takamatsu J, Shima M, Hanabusa H, Takedani H, Takashima Y, Matsushita T, Tawa A, Higasa S, Takata N, Sakai M, Kawakami K, Ohashi Y, Saito H. Shirahata A, et al. Among authors: saito h. Haemophilia. 2013 Mar;19(2):330-7. doi: 10.1111/hae.12024. Epub 2012 Sep 19. Haemophilia. 2013. PMID: 22989180 Clinical Trial.
A Phase II clinical trial of a mixture of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors: haemostatic efficacy, safety and pharmacokinetics/pharmacodynamics.
Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, Amano K, Takedani H, Tamashima S, Matsushita T, Tawa A, Tanaka I, Higasa S, Kosaka Y, Fujii T, Sakai M, Migita M, Kawakami K, Ohashi Y, Saito H. Shirahata A, et al. Among authors: saito h. Haemophilia. 2013 Nov;19(6):853-60. doi: 10.1111/hae.12205. Epub 2013 Jun 6. Haemophilia. 2013. PMID: 23738888 Clinical Trial.
A phase III clinical trial of a mixture agent of plasma-derived factor VIIa and factor X (MC710) in haemophilia patients with inhibitors.
Shinkoda Y, Shirahata A, Fukutake K, Takamatsu J, Shima M, Hanabusa H, Mugishima H, Takedani H, Kawasugi K, Taki M, Matsushita T, Tawa A, Nogami K, Higasa S, Kosaka Y, Fujii T, Sakai M, Migita M, Uchiba M, Kawakami K, Sameshima K, Ohashi Y, Saito H. Shinkoda Y, et al. Among authors: saito h. Haemophilia. 2017 Jan;23(1):59-66. doi: 10.1111/hae.13050. Epub 2016 Aug 1. Haemophilia. 2017. PMID: 27480904 Clinical Trial.
8,620 results